Search clinical trials for: Paclitaxel bevacizumab atezolizumab

Total 6650 results

University of Washington
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
Fudan University

Not yet recruiting

Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer (BETTER)

Non-small Cell Lung Cancer Metastatic
Genentech, Inc.

Completed

A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma (BEAM)

Melanoma
The Cleveland Clinic
Genentech, Inc.

Completed

Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer

Endometrial Carcinoma

United States
Genentech, Inc.

Completed

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Non-Squamous Non-Small Cell Lung Cancer

Australia, United States, Hungary, France, Germany, Czech Republic, Poland
First Affiliated Hospital of Zhejiang University
Hoffmann-La Roche; Geneplus-Beijing Co. Ltd.

Unknown

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

Non-Small Cell Lung Cancer

China
R-Pharm

Completed

A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

Metastatic Breast Cancer

Italy, United Kingdom, United States, France, Spain
Fondazione Michelangelo

Completed

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (NeoTRIPaPDL1)

Invasive Ductal Breast Carcinoma

Spain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
National University Hospital, Singapore

Recruiting

Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma

Singapore
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States
Shandong University

Recruiting

Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Objective Response Rate

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Holy Cross Hospital, Florida

Terminated

Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer (HCH003)

Non-Small-Cell Lung Carcinoma

United States
Akeso

Recruiting

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
Genentech, Inc.

Completed

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, France, Hungary, Australia, Brazil, Canada, Spain, Germany, United Kingdom, Chile, Israel, Italy, Netherlands, Argentina, Ukraine, Russian Federation
Genentech, Inc.

Terminated

A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

Metastatic Breast Cancer
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
Seoul National University Hospital

Unknown

The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer

Urothelial Carcinoma
Hoffmann-La Roche

Withdrawn

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma
Zhejiang Cancer Hospital

Recruiting

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
Spanish Lung Cancer Group

Completed

Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab (ANGIOMET)

Nonsquamous Nonsmall Cell Neoplasm of Lung

Spain
University of Chicago
National Cancer Institute (NCI)

Completed

Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Lung Cancer

United States
Centus Biotherapeutics Limited

Completed

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA)

Carcinoma, Non-Small-Cell Lung

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Georgia, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, Ukrain... and more
Pfizer

Completed

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Non-Small Cell Lung Cancer

Germany, Spain, Greece, Korea, Republic of, India, United States, Netherlands, Taiwan, Japan, Hungary, Russian Federation, Philippines, Poland, Australia, Brazil, Croatia, South Africa, Turkey, Romania, Chile, Ukraine, Bulgaria, Cze... and more
National Cancer Institute (NCI)

Completed

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States
Incyte Corporation
Hoffmann-La Roche; Genentech, Inc.

Terminated

A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

UC (Urothelial Cancer) | NSCLC (Non-small Cell Lung Carcinoma)

United States
Corvus Pharmaceuticals, Inc.
Genentech, Inc.

Completed

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Renal Cell Cancer | Metastatic Castration Resistant Prostate Cancer

United States, Canada, Australia
European Organisation for Research and Treatment...
Hoffmann-La Roche; Leap Therapeutics, Inc.

Withdrawn

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC)

Esophageal Cancer | Hepatobiliary Neoplasm | Biliary Tract Cancer | GastroEsophageal Cancer
M.D. Anderson Cancer Center

Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Chondrosarcoma | Advanced Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous... and other conditions

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Recruiting

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Carcinoma, Hepatocellular

Taiwan
Hoffmann-La Roche

Completed

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

Colorectal Cancer

Spain, United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Bladder Cancer

United States, France, Belgium, Korea, Republic of, United Kingdom, Czechia, Austria, Canada, Denmark, Greece, Italy, Netherlands, Portugal, Slovenia, Spain, Sweden, Turkey, Poland, Hungary, Switzerland, Japan, Taiwan, Australia, Norway, Germa... and more
M.D. Anderson Cancer Center

Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid Neoplasm | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage... and other conditions

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Withdrawn

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

United States
Loyola University
Genentech, Inc.; Celgene Corporation

Completed

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

United States
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
University Medical Center Groningen

Terminated

89Zr-atezolizumab PET Scan and Lobular Breast Cancer (ImaGelato)

Lobular Metastatic Breast Cancer

Netherlands
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
Sichuan Cancer Hospital and Research Institute

Recruiting

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Lung Diseases | Thoracic Neoplasms | Non-small Cell Lung Cancer | Pulmonary Sarcomatoid Carcinoma

China
The Methodist Hospital Research Institute
Genentech, Inc.

Not yet recruiting

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Hepatocellular Carcinoma | Hepatocellular Cancer

United States
Arjun Balar, MD
Hoosier Cancer Research Network; Roche-Genentech

Terminated

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Urothelial Carcinoma

United States
Queen Mary University of London
Hoffmann-La Roche; Asan Medical Center; Kliniken Essen-Mitte; MedSIR

Active, not recruiting

Pre-operative Immunotherapy Combination Strategies in Breast Cancer (ECLIPSE)

Breast Cancer | Estrogen Receptor-positive Breast Cancer

United Kingdom
Ardigen
National Center for Research and Development, Poland; The Institute of Bioorganic...

Unknown

Polish Microbiome Map

Melanoma | Healthy Volunteers | Metagenome | Immunotherapy | Microbiome

Poland
Immunicom Inc

Recruiting

Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

Non Small Cell Lung Cancer

Turkey
Columbia University
Genentech, Inc.; Celgene Corporation

Completed

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Carcinoma, Non-Small-Cell Lung

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States
The Netherlands Cancer Institute
Roche Pharma AG

Completed

Carboplatin-cyclophosphamide Combined With Atezolizumab (PROLOG)

Breast Cancer | Ovarian Cancer | Cervix Cancer | Endometrial Cancer

Netherlands
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
Swiss Group for Clinical Cancer Research

Completed

Metronomic Therapy in Metastatic Breast Cancer.

Breast Cancer

Switzerland

Search clinical trials for: Paclitaxel bevacizumab atezolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations